HUE032973T2 - Hosszú ideig ható koagulációs faktorok és elõállítási eljárásuk - Google Patents

Hosszú ideig ható koagulációs faktorok és elõállítási eljárásuk Download PDF

Info

Publication number
HUE032973T2
HUE032973T2 HUE10796803A HUE10796803A HUE032973T2 HU E032973 T2 HUE032973 T2 HU E032973T2 HU E10796803 A HUE10796803 A HU E10796803A HU E10796803 A HUE10796803 A HU E10796803A HU E032973 T2 HUE032973 T2 HU E032973T2
Authority
HU
Hungary
Prior art keywords
factor
ctp
coagulation factor
coagulation
another embodiment
Prior art date
Application number
HUE10796803A
Other languages
English (en)
Inventor
Udi Eyal Fima
Gili Hart
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of HUE032973T2 publication Critical patent/HUE032973T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)

Claims (17)

Hosszú ideig haló koaguláeiós faktorok és előállítási eljárásuk SZABAD ALMI IGÉNYPONTOK
1. Polipeptid. amely a következő komponenseket tartalmazza: egy koaguláeiós faktor, valamint öt. bmpáo korfongonadotropin C-íermínáils pepiid (CTP-k), a szóban forgó koaguláeiós faktor C-termlnlisIhoz kapesöiódva, ahol a: szóban forgó koa-gulációs faktor a Víl-es faktor vagy a Vila faktog vagy egy koaguláció* faktor, valamint: három humán koriongonadotropin C-terminális peprid (CTP-k), a szóban forgó koaguláeiós Ikkfor CMerminálisához kapcsolódba, ahol a szóban forgó koaguláeiós faktor a ÖGeS faktor, a hol a sáófjan forgó CTP-k szekvenciája tartalmazza a 4, szántó: szekvencia: első 1 0 aminosavát (azaz tas SlSSICAf^PS amlnosav azckgenciáí).
2> ilps f, Igénypont szerinti pepiid, anmlyben legalább egy -Ctf szekvenciája egy, az 1, szántó szekvenciából Illetve a 2, szántó szelomneilbpi választható ammosav szekvenciái tartalmaz.
3. Az 1, vagy 2. igénypont szerinti poli pepiid., amelyben legalább egy OTP legalább egy glikozllezést bolyét tártalmáz.
4. Az 1-3. Igénypontok bfzmeiyike szerinti poll pepiid, amelyben legalább egy OTP egy linkeren keresztül kapcsolódik a szóban forgó koaguláeiós fWöorjfoz.
5. A 4. igénypont szerinti poüpeptM, amelyben a szöbtm forgo linker egy peptidkötés.
6. Gyógyászati készitmény, amely az 1-5. igénypontok bármelyike szerinti poiipegtidet tartalmazza,
7. Egy polmukleotid, amely tartalmaz egy kódoló részt, amely egy pölipeptideí kódol amely egy koaguláeiós faktorból valamint öt humán koriongonadotropin (Liermináiis pepiidből (CTP-fc) áll, a szóban forgó koaguláeiós faktor C-terminâbsâboz kapcsolódva, ahol a szóban forgó koaguláeiós faktor a VILes faktor vagy a Vila faktor, vagy ^y kódoló réss, amely egy polipeptlciet kódol, amely egy koaguláeiós faktorból valamim bárom humán koriongonadotropin C-terminális pepiidből (CTP-k) áll a szóban forgó koaguláeiós fokfor CAerrntnálisához kapcsolódva, aboi a szóban forgó koapláelós faktor a L¥~es faktor* ahol a szóban forgó CTP-k szekvenellp: tartalmazza a 4, számú szekvencia első 10 aminosavát.
8 Â ?. igénypont szerinti pöltgepfid, amelyben Ιρρίβ egy €TP szekvenciája egy, az 1 számú szekvenciából illetve a 2, számú szekvenciából választható aminosav szekvenciát tártál-máz,
9. Expresszios vektor, amely a 1. vagy 8. igénypont szerinti polmukieotidottartdmazza.
10. Sejt, amely tartalmazza a 9. igénypont szerinti expresszié* vektort.
11. Készítmény, amely a 9. igénypont szerinti expresszié* vektort tartalmazza.
12 Eljárás egy koaguláció* faktor biológiai létezési i dejének meghosszabbítására, azzal jellemezve, hogy a következő lépéseket tartalmazza· öt humán koriongonadotropin t-terminális pepiidet {CTP-k) kapcsolunk a szohanjorgó koa-ipiáéiós fo Cúertninálisához* aboi a szóban faktor a VIÍ~es faktor vagy a Vila »or, vágy három humán koriongonadotropin C-terminális pepiidet (CTP-k) kapcsolunk a szóban forgó koaguláció» faktor C-termlnálisához, ahol a szöbatt forgé koaguláció» faktor a ÍX-es faktor, ahol a szóban forgó CTP-k szekvenciája tártál mázzá a 4. számú szekvencia első 10 aminosavát, javítva ezzel a szóban forgó koaguláció» faktor biológiai felezési Idejét,
13. Eljárás egy koaguláeioa iÉtor görbe alatti területének ίΛΓΓ) megnöveléséi e, azzal jellemezve., hogy a következő lépésekettartáimazza; öt humán koriongonadotropin C-ierminális pepiidet (CTP-k) kapcsolunk a szóban forgó koa-pláéiös faktor CrtertninálíSához, aboi a szóban forgó koaguláció* faktor a ¥$*esdkkíof vágy a Vllá. faktor, vagy három humán koriongonadotropin €·terminális pepiidet (CTP-k) kapcsolunk a szóban forgó koagulációs faktor C-ternartálisához, aboi a szóban forgó koaguláció» fofefor a IX-es fokíort áboká szóban forgó CTP-k szekvenciája taríálrnazza a 4, számú szekvencia első 10 aninosavil, ja-yitva ezzel a szóban forgó koaguiáciős faktor AUC értékét
14. A 12. vagy 13 igénypont szerinti eljárás, azzal jellemezve, hogy a legalább égy koriongonadotropin CTP amlnosay szekvenciája vagy az 1. szántó szekvencia, vagy a % számú szekvencia.
15. Poiipeptid, amely tartalmaz egy koaguláció» faktort* valamint « humán koriohgona-dotropfo C-terminális peptídet (ClP-k), a szóban forgó koagulációs lódvá, ahol a szóban forgó CTP-k a 4, számú saeteeaoelá első 10 amino^vái-Étótó'mazEákíiimöiliá kezelésében történő alkalmazás céljára, ahol a szóban forgó koagulációs faktor a Vií-es faktor vagy a Vila fokiért
16. Polipepíki amely tartalmaz egy koagulácíos lakion, vaíamínt három humán koríongo-Mdottcpn CeiA pepiidet tC'TP-k), a szobán lengő feaägÄeios dicter fô4emunàï kához kap-osolódva, ahol a szóhlOT föí'gd Cf P^k ä 4. számú szekvencia első 10 amioosavát tartalmazzák; hemofi~ !?a kezelésében történd dkahhaááa eépm, ahol a szálán lúgé
17. A. 15 vagy 16. igénypont szerinti poli pepiid, amelyben a legalább egy konongona-dotrögin GTP aminosav szekvenciája vagy az I. számú szdkvsnsia,, vagy a X számú szekvencia.
HUE10796803A 2009-07-09 2010-07-01 Hosszú ideig ható koagulációs faktorok és elõállítási eljárásuk HUE032973T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22436609P 2009-07-09 2009-07-09

Publications (1)

Publication Number Publication Date
HUE032973T2 true HUE032973T2 (hu) 2017-11-28

Family

ID=43429620

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10796803A HUE032973T2 (hu) 2009-07-09 2010-07-01 Hosszú ideig ható koagulációs faktorok és elõállítási eljárásuk

Country Status (19)

Country Link
US (1) US8476234B2 (hu)
EP (2) EP3130346A1 (hu)
JP (3) JP5823960B2 (hu)
KR (3) KR102014844B1 (hu)
CN (2) CN102639144B (hu)
AU (1) AU2010269884B2 (hu)
CA (1) CA2767503C (hu)
CY (1) CY1118733T1 (hu)
DK (1) DK2451473T3 (hu)
ES (1) ES2618209T3 (hu)
HR (1) HRP20170051T1 (hu)
HU (1) HUE032973T2 (hu)
IL (2) IL235377A (hu)
LT (1) LT2451473T (hu)
MX (3) MX2012000469A (hu)
PL (1) PL2451473T3 (hu)
PT (1) PT2451473T (hu)
SI (1) SI2451473T1 (hu)
WO (1) WO2011004361A2 (hu)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553940B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3590949T3 (da) 2010-10-01 2022-07-11 Modernatx Inc Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
MY168754A (en) 2011-10-06 2018-11-30 Hanmi Science Co Ltd Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
JP6242819B2 (ja) * 2012-02-14 2017-12-06 オプコ バイオロジクス リミテッド 長時間作用型凝固因子およびその生成方法
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151667A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides
PE20142405A1 (es) * 2012-04-19 2015-01-25 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas
EP3970738A1 (en) * 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
ES2882890T3 (es) 2012-11-20 2021-12-03 Opko Biologics Ltd Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
WO2014088836A1 (en) * 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
PT2956477T (pt) 2013-02-15 2021-02-05 Bioverativ Therapeutics Inc Gene do fator viii otimizado
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
KR102444140B1 (ko) * 2013-10-21 2022-09-15 옵코 바이오로직스 리미티드 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
SG11201704706RA (en) * 2014-12-10 2017-07-28 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
WO2016203482A2 (en) * 2015-06-19 2016-12-22 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN106397571A (zh) * 2015-07-31 2017-02-15 李金松 一种新型羧基末端肽及长效白介素7
CN106397570B (zh) * 2015-07-31 2019-11-15 袁武梅 一种羧基末端肽及长效干扰素
US11560418B2 (en) 2015-10-20 2023-01-24 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX fusion proteins
DK3411478T3 (da) 2016-02-01 2022-09-12 Bioverativ Therapeutics Inc Optimerede faktor viii-gener
BR112019000610A2 (pt) * 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
CN106279436B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 活化的人凝血因子vii融合蛋白及其制备方法与用途
CN107759694B (zh) * 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN110438022A (zh) * 2018-10-10 2019-11-12 福建师范大学 一种前体蛋白Kex2过表达毕赤酵母菌株及其构建方法
BR112021017062A2 (pt) 2019-03-19 2021-11-16 CSL Behring Lengnau AG Variantes do fator ix e usos das mesmas em terapia
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US130060A (en) * 1872-07-30 Improvement in cotton-presses
US190611A (en) * 1877-05-08 Improvement in protractors
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
JPS5781447A (en) * 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
ATE110571T1 (de) 1988-05-06 1994-09-15 Toray Industries Stabile interferon-beta-zusammensetzung.
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5705478A (en) 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5338835A (en) * 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
CA2053864C (en) 1989-02-21 2001-11-20 Irving Boime Modified forms of reproductive hormones
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US7217689B1 (en) * 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US6028177A (en) 1991-10-04 2000-02-22 Washington University Methods of detecting single-chain forms of the glycoprotein hormone quartet
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2160800C (en) 1993-04-20 2010-06-01 Irving Boime Ctp modified gonadotropic proteins
US6737515B2 (en) * 1993-11-19 2004-05-18 Washington University Follicle stimulating hormone-glycosylation analogs
US6238890B1 (en) * 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
MX9601320A (es) 1994-08-12 1997-05-31 Univ Washington Formas de cadena unica de cuarteto de hormona de glicoproteina.
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
BR9915548A (pt) 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
US20020127652A1 (en) * 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US7094566B2 (en) * 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
ATE416784T1 (de) * 2000-12-01 2008-12-15 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
JP4409135B2 (ja) 2000-12-01 2010-02-03 武田薬品工業株式会社 生理活性物質含有製剤の製造法
PL209550B1 (pl) * 2000-12-07 2011-09-30 Lilly Co Eli Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulinoniezależną i kompozycja do leczenia pacjentów z otyłością
KR101229995B1 (ko) * 2000-12-11 2013-02-06 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
EP1342730B1 (en) 2000-12-11 2006-03-15 Cheil Jedang Corporation Fusion protein having the enhanced in vivo activity of erythropoietin
US8637077B2 (en) * 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
JP5160005B2 (ja) 2000-12-28 2013-03-13 武田薬品工業株式会社 徐放性製剤
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP1997829A1 (en) * 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
US7173113B2 (en) * 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
US7081446B2 (en) * 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
GB0206048D0 (en) 2002-03-14 2002-04-24 Croda Int Plc Use
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
JP4683319B2 (ja) 2003-02-19 2011-05-18 武田薬品工業株式会社 徐放性製剤用の分散剤
WO2004073749A1 (ja) * 2003-02-19 2004-09-02 Takeda Pharmaceutical Company Limited 徐放性製剤用の分散剤
US7649084B2 (en) * 2003-11-12 2010-01-19 University Of Georgia Research Foundation, Inc. Recombinant glycoproteins related to feline thyrotropin
CA2549486C (en) * 2003-12-19 2015-04-14 F. Hoffmann-La Roche Ag Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
JP5037331B2 (ja) * 2004-03-19 2012-09-26 バクスター・インターナショナル・インコーポレイテッド 出血性障害の処置のための第ｉｘａ因子
CA2592521A1 (en) * 2004-08-17 2006-02-23 Csl Behring Gmbh Modified vitamin k dependent polypeptides
EP1728798A1 (en) * 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
US8048848B2 (en) * 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US7553940B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same

Also Published As

Publication number Publication date
IL242368B (en) 2019-01-31
KR101950961B1 (ko) 2019-02-21
CN105153314A (zh) 2015-12-16
EP2451473B1 (en) 2016-10-19
CY1118733T1 (el) 2017-07-12
AU2010269884B2 (en) 2015-01-15
EP2451473A4 (en) 2013-04-03
AU2010269884A1 (en) 2012-02-02
JP2016040293A (ja) 2016-03-24
WO2011004361A2 (en) 2011-01-13
LT2451473T (lt) 2017-04-10
JP2012532601A (ja) 2012-12-20
KR20120089445A (ko) 2012-08-10
JP6162769B2 (ja) 2017-07-12
HRP20170051T1 (hr) 2017-03-24
CA2767503C (en) 2017-03-14
CA2767503A1 (en) 2011-01-13
PT2451473T (pt) 2017-01-27
MX2012000469A (es) 2012-03-26
DK2451473T3 (en) 2017-01-30
PL2451473T3 (pl) 2017-09-29
US8476234B2 (en) 2013-07-02
EP2451473A2 (en) 2012-05-16
KR102014844B1 (ko) 2019-08-27
WO2011004361A3 (en) 2011-06-03
US20100317585A1 (en) 2010-12-16
JP2018008935A (ja) 2018-01-18
KR101802919B1 (ko) 2017-11-29
MX346920B (es) 2017-04-05
JP5823960B2 (ja) 2015-11-25
KR20190018063A (ko) 2019-02-20
EP3130346A1 (en) 2017-02-15
CN102639144B (zh) 2015-10-21
SI2451473T1 (sl) 2017-06-30
IL235377A (en) 2017-04-30
MX2021012106A (es) 2022-06-14
ES2618209T3 (es) 2017-06-21
KR20170132904A (ko) 2017-12-04
CN102639144A (zh) 2012-08-15
JP6430592B2 (ja) 2018-11-28

Similar Documents

Publication Publication Date Title
JP6430592B2 (ja) 長期作用性凝固因子およびそれを製造する方法
US8759292B2 (en) Long-acting coagulation factors and methods of producing same
US9458444B2 (en) Long-acting coagulation factors and methods of producing same
AU2016202829B2 (en) Long-acting coagulation factors and methods of producing same
US11066658B2 (en) Long-acting coagulation factors and methods of producing same
AU2017201513B2 (en) Long-acting coagulation factors and methods of producing same
US20220170005A1 (en) Long-acting coagulation factors and methods of producing same